Sunitinib in hepatocellular carcinoma: Redefining appropriate dosing, schedule, and activity end points

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages

  Faivre, Sandrine J ^a   Bouattour, Mohamed ^a   Dreyer, Chantal ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANGIOGENESIS; ASCITES; ASIAN; ASTHENIA; BRAIN DISEASE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; ESOPHAGUS VARICES BLEEDING; HAND FOOT SYNDROME; HUMAN; KIDNEY CANCER; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; OVERALL SURVIVAL; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; BIOASSAY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; LIVER TUMOR; NOTE; PHASE 3 CLINICAL TRIAL; RADIOGRAPHY; TIME; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; HUMANS; INDOLES; LIVER NEOPLASMS; PYRROLES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 73349110120     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.0670     Document Type: Letter

References (14)

1. Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 27:3027-3035, 2009
2. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
3. Zhu AX, Raymond E: Early development of sunitinib in hepatocellular carcinoma. Expert Rev Anticancer Ther 9:143-150, 2009
4. Faivre S, Raymond E, Boucher E, et al: Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-lebel, multicentre, phase II study. Lancet Oncol 10:743-744, 2009
5. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
6. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
7. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
8. Bello CL, Garrett M, Smeraglia J, et al: Pharmacokinetics (PK) of sunitinib malate (SU11248) in subjects with hepatic impairment. Ann Oncol 17:148, 2006 (suppl 9)
9. Blay JY, George S, Casali R, et al: Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing. Eur J Cancer 5:402, 2007 (suppl; abstr 7501)
10. Koeberle D, Montemurro M, Samaras P, et al: Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trial (SAKK 77/06 and SASL 23). J Clin Oncol 27:224s, 2009 (suppl; abstr 4591)
11. Faivre S, Demetri G, Sargent W, Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745, 2007
12. Faivre S, Raymond E, Douillard J, et al: Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 25:149s, 2007 (suppl; abstr 3546)
13. Benjamin RS, Choi H, Macapinlac HA, et al: We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-1764, 2007
14. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759, 2007